KFA
DGX icon

Krane Funds Advisors’s Quest Diagnostics DGX Stock Holding History

Krane Funds Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,296
Closed -$397K – 324
2021
Q4 		$397K Sell
2,296
-397
-15% -$60.4K 0.01% 179
2021
Q3 		$391K Sell
2,693
-1,600
-37% -$234K 0.01% 230
2021
Q2 		$567K Buy
+4,293
New +$562K 0.02% 149

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Krane Funds Advisors's DGX Position: Q1 2022 in Review

Krane Funds Advisors sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 2,296 shares — an estimated $397K sold.

Krane Funds Advisors first reported a position in DGX in Q2 2021 and held it in 3 quarters. The position peaked at $567K in Q2 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

  • Krane Funds Advisors reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Krane Funds Advisors sold 2,296 Quest Diagnostics shares in Q1 2022, an estimated $397K.
  • Krane Funds Advisors first reported a position in Quest Diagnostics in Q2 2021 and held it in 3 quarters.
  • Krane Funds Advisors's Quest Diagnostics position peaked at $567K in Q2 2021.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Krane Funds Advisors's 13F filing for Q1 2022, filed 11 May 2022.